SensArs secures EUR 1.1 million to advance neuromodulation technology

SensArs, an EPFL spin-off specialized in neuromodulation technology for treating chronic pain and sensory loss, has secured a pre-seed investment from HTH and two grants worth EUR 1.1 million.

Founded in 2014 as a spin-off of EPFL, SensArs specializes in neuromodulation technology aimed at providing relief for chronic pain and sensory loss. The company’s innovative approach combines advanced wearable sensors with AI-driven software to create personalized treatment plans for patients, significantly improving their quality of life.

SensArs has received a EUR 500,000 grant from the Eurostars program for its latest project, SENSOLE. The project aims to create the world’s first system capable of monitoring and treating gait disabilities and pain in patients with leg neuropathy-induced sensory loss. SENSOLE features wearable sensors that provide detailed data on leg movement and pressure points across different areas of the foot. When paired with a neurostimulator, SENSOLE works to alleviate neuropathy complications by restoring real-time sensory feedback. The system uses AI-driven software to offer personalized treatment guidance based on individual patient data.

In a parallel development, SensArs Germany, the German subsidiary of SensArs, has secured a EUR 600,000 grant from the German Federal Ministry of Education and Research (BMBF). This grant will support research initiatives focused on testing SENSY, SensArs’ patented implantable neurostimulator, in amputees. In collaboration with the University of Heidelberg, this endeavor will evaluate SENSY’s effectiveness in managing pain for amputees, advancing SensArs’ mission to innovate in the field of neuromodulation.

Transforming the landscape of neuromodulation

Additionally, SensArs has secured a pre-seed investment from HTH, an Italian venture capital investor dedicated to improving human health. “We are thrilled to receive these investments and grants, which underscore the confidence in our innovative technologies and the potential impact they can have on patients’ lives,” said Francesco Petrini, CEO of SensArs. “With these resources, we are well-positioned to accelerate our research and development efforts, bringing us closer to our goal of transforming the landscape of neuromodulation and offering hope to millions of individuals suffering from chronic pain and sensory loss.”

Guy Siman, COO of SensArs, added, “These advancements mark significant milestones in our journey towards enhancing the efficacy and accessibility of neuromodulation treatments. We are committed to leveraging these resources to drive innovation and deliver tangible solutions that address the unmet needs of patients worldwide.”